March 10, 2023
Bulletin interne de l'Institut Pasteur
A new breakthrough in the development of an effective vaccine for allergic asthma
Scientists from Inserm, the CNRS and Université Toulouse III–Paul Sabatier in the Infinity Laboratory, and from the Institut Pasteur and the French company NEOVACS are developing and testing a new vaccine to tackle allergic asthma, which affects millions of people worldwide. In their latest study, the teams showed that the vaccine was effective in producing antibodies capable of neutralizing cytokines IL-4 and IL-13, proteins in the human immune system that play a key role in triggering allergic asthma. The findings, published in the journal Allergy, pave the way for the organization of a clinical trial.